BioGX Expands Xfree Respiratory PCR With COVID-19/Flu A/Flu B Multiplex, Group A Streptococcus, Mycoplasma Pneumoniae

11 September 2023

BioGX, a global provider of molecular diagnostic solutions, announces the availability of three new Xfree™ Direct-Sample-to-Answer PCR multiplexes for the detection of Group A Streptococcus, Mycoplasma pneumoniae and Flu A, Flu B, COVID-19 N1/RdRp. Xfree Flu A, Flu B, COVID-19 and Group A Streptococcus were previously CE-IVD marked while Mycoplasma pneumoniae is available as research use only. Laboratories can request custom manufactured formats for high-throughput use that may be validated for their intended use on a variety of real-time PCR platforms including, the BioGX pixl™, Applied Biosystems 7500, ThermoFisher QuantStudio and Bio-Rad CFX Touch. 

"Our Xfree chemistry has proven to be highly robust in our FDA-EUA COVID-19 test. We are excited to offer expanded respiratory panels to  equip our customers with cost-effective, rapid PCR  workflows," said Shahin Iqbal, Ph.D., President & COO of BioGX.

Xfree technology provides a complete lyophilized test in a single tube in the trusted BioGX Sample-Ready™ format for extraction-free, direct sample addition real-time PCR testing. This format eliminates pre-treatment and nucleic acid extraction steps, enabling labs with a simple Sample-to-Answer workflow. The test can be shipped anywhere in the world without refrigeration.

To request more information on BioGX Xfree products and our other testing solutions, please contact

Privacy Policy
We have updated our privacy policy. In the latest update it explains what cookies are and how we use them on our site. To learn more about cookies and their benefits, please view our privacy policy. Please be aware that parts of this site will not function correctly if you disable cookies. By continuing to use this site, you consent to our use of cookies in accordance with our privacy policy unless you have disabled them.